Guillain-Barré syndrome in a patient on adalimumab for the treatment of psoriasis

Abstract

Abstract The use of TNF-α inhibitors for the treatment of moderate to severe psoriasis and psoriatic arthritis is increasingly more frequent. The authors report a case of Guillain-Barré syndrome as a late manifestation of the treatment with adalimumab. Although unusual, this is relevant for professionals who prescribe biologic drugs. We also stress the importance of investigating the past and family medical history regarding demyelinating diseases before starting treatment.

Keywords

• Arthritis, psoriatic
• Demyelinating diseases
• Psoriasis
• Guillain-Barre syndrome